Hyaluronan, inflammation, and breast cancer progression

Frontiers in Immunology

Volumn 6, Issue JUN, 2015, Pages

  Schwertfeger, Kathryn L ^a   Cowman, Mary K ^b   Telmer, Patrick G ^c   Turley, Eva A ^c   McCarthy, James B ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b POLYTECHNIC UNIVERSITY   (United States)

^c WESTERN UNIVERSITY   (Canada)

Author keywords

Breast cancer; CD44; Hyaluronan; Inflammation; macrophage; RHAMM HMMR; Tumor microenvironment

Indexed keywords

BIVATUZUMAB; CD163 ANTIGEN; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR 2; GELATINASE B; HERMES ANTIGEN; HYALURONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PLATELET DERIVED GROWTH FACTOR; PROGESTERONE RECEPTOR; PROTEIN BCL 2; STAT3 PROTEIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; BREAST CANCER; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL MIGRATION; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATION; INTRADUCTAL CARCINOMA; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84935135038     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00236     Document Type: Review

References (130)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature (2002) 420:860-7. doi: 10.1038/nature01322
2. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell (2006) 124:263-6. doi:10.1016/j.cell.2006.01.007
3. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell (2010) 141:39-51. doi:10.1016/j.cell.2010.03.014
4. Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends Immunol (2012) 33:119-26. doi:10.1016/j.it.2011.12.001
5. Tolg C, Mccarthy JB, Yazdani A, Turley EA. Hyaluronan and RHAMM in wound repair and the "cancerization" of stromal tissues. Biomed Res Int (2014) 2014:103923. doi:10.1155/2014/103923
6. Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer (2004) 4:528-39. doi:10.1038/nrc1391
7. Bourguignon LY, Wong G, Earle C, Krueger K, Spevak CC. Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J Biol Chem (2010) 285:36721-35. doi:10.1074/jbc.M110.162305
8. Li Y, Li L, Brown TJ, Heldin P. Silencing of hyaluronan synthase 2 suppresses the malignant phenotype of invasive breast cancer cells. Int J Cancer (2007) 120:2557-67. doi:10.1002/ijc.22550
9. 2) promotes breast cancer cell invasion by suppression of tissue metalloproteinase inhibitor 1 (TIMP-1). J Biol Chem (2011) 286:42349-59. doi:10.1074/jbc.M111.278598
10. Koyama H, Hibi T, Isogai Z, Yoneda M, Fujimori M, Amano J, et al. Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment: possible involvement of versican/PG-M. Am J Pathol (2007) 170:1086-99. doi:10.2353/ajpath.2007.060793
11. West DC, Kumar S. Hyaluronan and angiogenesis. Ciba Found Symp (1989) 143:187-201 discussion 201-187, 281-185.
12. Auvinen P, Tammi R, Parkkinen J, Tammi M, Agren U, Johansson R, et al. Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol (2000) 156:529-36. doi:10.1016/S0002-9440(10)64757-8
13. Corte MD, Gonzalez LO, Junquera S, Bongera M, Allende MT, Vizoso FJ. Analysis of the expression of hyaluronan in intraductal and invasive carcinomas of the breast. J Cancer Res Clin Oncol (2010) 136:745-50. doi:10.1007/s00432-009-0713-2
14. Assmann V, Gillett CE, Poulsom R, Ryder K, Hart IR, Hanby AM. The pattern of expression of the microtubule-binding protein RHAMM/IHABP in mammary carcinoma suggests a role in the invasive behaviour of tumour cells. J Pathol (2001) 195:191-6. doi:10.1002/path.941
15. Wang XY, Tan JX, Vasse M, Delpech B, Ren GS. Comparison of hyaluronidase expression, invasiveness and tubule formation promotion in ER (-) and ER (+) breast cancer cell lines in vitro. Chin Med J (Engl) (2009) 122:1300-4.
16. Auvinen P, Tammi R, Kosma VM, Sironen R, Soini Y, Mannermaa A, et al. Increased hyaluronan content and stromal cell CD44 associate with HER2 positivity and poor prognosis in human breast cancer. Int J Cancer (2013) 132:531-9. doi:10.1002/ijc.27707
17. Auvinen P, Rilla K, Tumelius R, Tammi M, Sironen R, Soini Y, et al. Hyaluronan synthases (HAS1-3) in stromal and malignant cells correlate with breast cancer grade and predict patient survival. Breast Cancer Res Treat (2014) 143:277-86. doi:10.1007/s10549-013-2804-7
18. Lien HC, Lee YH, Jeng YM, Lin CH, Lu YS, Yao YT. Differential expression of hyaluronan synthase 2 in breast carcinoma and its biological significance. Histopathology (2014) 65:328-39. doi:10.1111/his.12390
19. Heldin P, Basu K, Olofsson B, Porsch H, Kozlova I, Kahata K. Deregulation of hyaluronan synthesis, degradation and binding promotes breast cancer. J Biochem (2013) 154:395-408. doi:10.1093/jb/mvt085
20. 2 and CD44 in breast tumorigenesis. Adv Cancer Res (2014) 123:211-29. doi:10.1016/B978-0-12-800092-2.00008-3
21. Weigel PH, Hascall VC, Tammi M. Hyaluronan synthases. J Biol Chem (1997) 272:13997-4000. doi:10.1074/jbc.272.22.13997
22. Itano N, Kimata K. Mammalian hyaluronan synthases. IUBMB Life (2002) 54:195-9. doi:10.1080/15216540214929
23. Tammi RH, Passi AG, Rilla K, Karousou E, Vigetti D, Makkonen K, et al. Transcriptional and post-translational regulation of hyaluronan synthesis. FEBS J (2011) 278:1419-28. doi:10.1111/j.1742-4658.2011.08070.x
24. Toole BP. Hyaluronan-CD44 interactions in cancer: paradoxes and possibilities. Clin Cancer Res (2009) 15:7462-8. doi:10.1158/1078-0432.CCR-09-0479
25. Kakizaki I, Kojima K, Takagaki K, Endo M, Kannagi R, Ito M, et al. A novel mechanism for the inhibition of hyaluronan biosynthesis by 4-methylumbelliferone. J Biol Chem (2004) 279:33281-9. doi:10.1074/jbc.M405918200
26. Spicer AP, Seldin MF, Olsen AS, Brown N, Wells DE, Doggett NA, et al. Chromosomal localization of the human and mouse hyaluronan synthase genes. Genomics (1997) 41:493-7. doi:10.1006/geno.1997.4696
27. Jiang D, Liang J, Noble PW. Hyaluronan as an immune regulator in human diseases. Physiol Rev (2011) 91:221-64. doi:10.1152/physrev.00052.2009
28. Bourguignon LY, Gilad E, Peyrollier K. Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration. J Biol Chem (2007) 282:19426-41. doi:10.1074/jbc.M610054200
29. Tian X, Azpurua J, Hine C, Vaidya A, Myakishev-Rempel M, Ablaeva J, et al. High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature (2013) 499:346-9. doi:10.1038/nature12234
30. Stern R, Asari AA, Sugahara KN. Hyaluronan fragments: an information-rich system. Eur J Cell Biol (2006) 85:699-715. doi:10.1016/j.ejcb.2006.05.009
31. Tolg C, Telmer P, Turley E. Specific sizes of hyaluronan oligosaccharides stimulate fibroblast migration and excisional wound repair. PLoS One (2014) 9:e88479. doi:10.1371/journal.pone.0088479
32. Yang C, Cao M, Liu H, He Y, Xu J, Du Y, et al. The high and low molecular weight forms of hyaluronan have distinct effects on CD44 clustering. J Biol Chem (2012) 287:43094-107. doi:10.1074/jbc.M112.349209
33. Rizzardi AE, Vogel RI, Koopmeiners JS, Forster CL, Marston LO, Rosener NK, et al. Elevated hyaluronan and hyaluronan-mediated motility receptor are associated with biochemical failure in patients with intermediate-grade prostate tumors. Cancer (2014) 120:1800-9. doi:10.1002/cncr.28646
34. Tolg C, Hamilton SR, Zalinska E, Mcculloch L, Amin R, Akentieva N, et al. A RHAMM mimetic peptide blocks hyaluronan signaling and reduces inflammation and fibrogenesis in excisional skin wounds. Am J Pathol (2012) 181:1250-70. doi:10.1016/j.ajpath.2012.06.036
35. Yuan H, Amin R, Ye X, De La Motte CA, Cowman MK. Determination of hyaluronan molecular mass distribution in human breast milk. Anal Biochem (2015) 474:78-88. doi:10.1016/j.ab.2014.12.020
36. Cowman MK, Lee H-G, Schwertfeger KL, McCarthy JB, Turley EA. The content and size of hyaluronan in biological fluids and tissues. Front Immunol (2015) 6:261. doi:10.3389/fimmu.2015.00261
37. Lepperdinger G, Strobl B, Kreil G. HYAL2, a human gene expressed in many cells, encodes a lysosomal hyaluronidase with a novel type of specificity. J Biol Chem (1998) 273:22466-70. doi:10.1074/jbc.273.35.22466
38. Eberlein M, Scheibner KA, Black KE, Collins SL, Chan-Li Y, Powell JD, et al. Anti-oxidant inhibition of hyaluronan fragment-induced inflammatory gene expression. J Inflamm (Lond) (2008) 5:20. doi:10.1186/1476-9255-5-20
39. Li M, Rosenfeld L, Vilar RE, Cowman MK. Degradation of hyaluronan by peroxynitrite. Arch Biochem Biophys (1997) 341:245-50. doi:10.1006/abbi.1997.9970
40. Tolg C, Hamilton SR, Nakrieko KA, Kooshesh F, Walton P, Mccarthy JB, et al. Rhamm-/-fibroblasts are defective in CD44-mediated ERK1,2 motogenic signaling, leading to defective skin wound repair. J Cell Biol (2006) 175:1017-28. doi:10.1083/jcb.200511027
41. Li H, Moll J, Winkler A, Frappart L, Brunet S, Hamann J, et al. RHAMM deficiency disrupts folliculogenesis resulting in female hypofertility. Biol Open (2015) 4:562-71. doi:10.1242/bio.201410892
42. Assmann V, Jenkinson D, Marshall JF, Hart IR. The intracellular hyaluronan receptor RHAMM/IHABP interacts with microtubules and actin filaments. J Cell Sci (1999) 112(Pt 22):3943-54.
43. Mohapatra S, Yang X, Wright JA, Turley EA, Greenberg AH. Soluble hyaluronan receptor RHAMM induces mitotic arrest by suppressing Cdc2 and cyclin B1 expression. J Exp Med (1996) 183:1663-8. doi:10.1084/jem.183.4.1663
44. Maxwell CA, Mccarthy J, Turley E. Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions? J Cell Sci (2008) 121:925-32. doi:10.1242/jcs.022038
45. Hamilton SR, Fard SF, Paiwand FF, Tolg C, Veiseh M, Wang C, et al. The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J Biol Chem (2007) 282:16667-80. doi:10.1074/jbc.M702078200
46. Zhang S, Chang MC, Zylka D, Turley S, Harrison R, Turley EA. The hyaluronan receptor RHAMM regulates extracellular-regulated kinase. J Biol Chem (1998) 273:11342-8. doi:10.1074/jbc.273.18.11342
47. Nikitovic D, Kouvidi K, Karamanos NK, Tzanakakis GN. The roles of hyaluronan/RHAMM/CD44 and their respective interactions along the insidious pathways of fibrosarcoma progression. Biomed Res Int (2013) 2013:929531. doi:10.1155/2013/929531
48. Banerji S, Ni J, Wang SX, Clasper S, Su J, Tammi R, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol (1999) 144:789-801. doi:10.1083/jcb.144.4.789
49. Jackson DG, Prevo R, Clasper S, Banerji S. LYVE-1, the lymphatic system and tumor lymphangiogenesis. Trends Immunol (2001) 22:317-21. doi:10.1016/S1471-4906(01)01936-6
50. Banerji S, Hide BR, James JR, Noble ME, Jackson DG. Distinctive properties of the hyaluronan-binding domain in the lymphatic endothelial receptor Lyve-1 and their implications for receptor function. J Biol Chem (2010) 285:10724-35. doi:10.1074/jbc.M109.047647
51. Prevo R, Banerji S, Ferguson DJ, Clasper S, Jackson DG. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium. J Biol Chem (2001) 276:19420-30. doi:10.1074/jbc.M011004200
52. Huang SS, Liu IH, Smith T, Shah MR, Johnson FE, Huang JS. CRSBP-1/LYVE-L-null mice exhibit identifiable morphological and functional alterations of lymphatic capillary vessels. FEBS Lett (2006) 580:6259-68. doi:10.1016/j.febslet.2006.10.028
53. Gale NW, Prevo R, Espinosa J, Ferguson DJ, Dominguez MG, Yancopoulos GD, et al. Normal lymphatic development and function in mice deficient for the lymphatic hyaluronan receptor LYVE-1. Mol Cell Biol (2007) 27:595-604. doi:10.1128/MCB.01503-06
54. Bono P, Wasenius VM, Heikkila P, Lundin J, Jackson DG, Joensuu H. High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer. Clin Cancer Res (2004) 10:7144-9. doi:10.1158/1078-0432.CCR-03-0826
55. Du Y, Liu Y, Wang Y, He Y, Yang C, Gao F. LYVE-1 enhances the adhesion of HS-578T cells to COS-7 cells via hyaluronan. Clin Invest Med (2011) 34:E45-54.
56. Schledzewski K, Falkowski M, Moldenhauer G, Metharom P, Kzhyshkowska J, Ganss R, et al. Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis. J Pathol (2006) 209:67-77. doi:10.1002/path.1942
57. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol (2002) 196:254-65. doi:10.1002/path.1027
58. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci (2008) 13:453-61. doi:10.2741/2692
59. Biswas SK, Sica A, Lewis CE. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol (2008) 180:2011-7. doi:10.4049/jimmunol.180.4.2011
60. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 4:71-8. doi:10.1038/nrc1256
61. Saari H. Oxygen derived free radicals and synovial fluid hyaluronate. Ann Rheum Dis (1991) 50:389-92. doi:10.1136/ard.50.6.389
62. Saari H, Konttinen YT, Friman C, Sorsa T. Differential effects of reactive oxygen species on native synovial fluid and purified human umbilical cord hyaluronate. Inflammation (1993) 17:403-15. doi:10.1007/BF00916581
63. Tiainen S, Tumelius R, Rilla K, Hamalainen K, Tammi M, Tammi R, et al. High numbers of macrophages, especially M2-like (CD163-positive), correlate with hyaluronan accumulation and poor outcome in breast cancer. Histopathology (2014) 66(6):873-83. doi:10.1111/his.12607
64. Noble PW, Lake FR, Henson PM, Riches DW. Hyaluronate activation of CD44 induces insulin-like growth factor-1 expression by a tumor necrosis factor-alpha-dependent mechanism in murine macrophages. J Clin Invest (1993) 91:2368-77. doi:10.1172/JCI116469
65. Kurtzman SH, Anderson KH, Wang Y, Miller LJ, Renna M, Stankus M, et al. Cytokines in human breast cancer: IL-1alpha and IL-1beta expression. Oncol Rep (1999) 6:65-70.
66. Pantschenko AG, Pushkar I, Anderson KH, Wang Y, Miller LJ, Kurtzman SH, et al. The interleukin-1 family of cytokines and receptors in human breast cancer: implications for tumor progression. Int J Oncol (2003) 23: 269-84. doi:10.3892/ijo.23.2.269
67. Nicolini A, Carpi A, Rossi G. Cytokines in breast cancer. Cytokine Growth Factor Rev (2006) 17:325-37. doi:10.1016/j.cytogfr.2006.07.002
68. Jin L, Yuan RQ, Fuchs A, Yao Y, Joseph A, Schwall R, et al. Expression of interleukin-1beta in human breast carcinoma. Cancer (1997) 80:421-34. doi:10.1002/(SICI)1097-0142(19970801)80:3<421::AID-CNCR10>3.0.CO;2-Z
69. Nie D. Cyclooxygenases and lipoxygenases in prostate and breast cancers. Front Biosci (2007) 12:1574-85. doi:10.2741/2170
70. Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol (2006) 176:284-90. doi:10.4049/jimmunol.176.1.284
71. Bertrand P, Girard N, Duval C, D'Anjou J, Chauzy C, Menard JF, et al. Increased hyaluronidase levels in breast tumor metastases. Int J Cancer (1997) 73:327-31. doi:10.1002/(SICI)1097-0215(19971104)73:3<327::AID-IJC4>3.0.CO,2-1
72. Tan JX, Wang XY, Li HY, Su XL, Wang L, Ran L, et al. HYAL1 overexpression is correlated with the malignant behavior of human breast cancer. Int J Cancer (2011) 128:1303-15. doi:10.1002/ijc.25460
73. Karihtala P, Soini Y, Auvinen P, Tammi R, Tammi M, Kosma VM. Hyaluronan in breast cancer: correlations with nitric oxide synthases and tyrosine nitrosylation. J Histochem Cytochem (2007) 55:1191-8. doi:10.1369/jhc.7A7270.2007
74. Wu M, Cao M, He Y, Liu Y, Yang C, Du Y, et al. A novel role of low molecular weight hyaluronan in breast cancer metastasis. FASEB J (2015) 29(4):1290-8. doi:10.1096/fj.14-259978
75. Tan JX, Wang XY, Su XL, Li HY, Shi Y, Wang L, et al. Upregulation of HYAL1 expression in breast cancer promoted tumor cell proliferation, migration, invasion and angiogenesis. PLoS One (2011) 6:e22836. doi:10.1371/journal.pone.0022836
76. Poola I, Abraham J, Marshalleck JJ, Yue Q, Lokeshwar VB, Bonney G, et al. Molecular risk assessment for breast cancer development in patients with ductal hyperplasias. Clin Cancer Res (2008) 14:1274-80. doi:10.1158/1078-0432.CCR-07-4053
77. Baeva LF, Lyle DB, Rios M, Langone JJ, Lightfoote MM. Different molecular weight hyaluronic acid effects on human macrophage interleukin 1beta production. J Biomed Mater Res A (2014) 102:305-14. doi:10.1002/jbm.a.34704
78. Kuang DM, Wu Y, Chen N, Cheng J, Zhuang SM, Zheng L. Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes. Blood (2007) 110:587-95. doi:10.1182/blood-2007-01-068031
79. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol (2005) 78:1043-51. doi:10.1189/jlb.0705358
80. Yang C, He L, He P, Liu Y, Wang W, He Y, et al. Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway. Med Oncol (2015) 32:352. doi:10.1007/s12032-014-0352-6
81. McKee CM, Lowenstein CJ, Horton MR, Wu J, Bao C, Chin BY, et al. Hyaluronan fragments induce nitric-oxide synthase in murine macrophages through a nuclear factor kappaB-dependent mechanism. J Biol Chem (1997) 272:8013-8. doi:10.1074/jbc.272.12.8013
82. Balkwill FR. The chemokine system and cancer. J Pathol (2012) 226:148-57. doi:10.1002/path.3029
83. Singh JK, Farnie G, Bundred NJ, Simoes BM, Shergill A, Landberg G, et al. Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clin Cancer Res (2013) 19:643-56. doi:10.1158/1078-0432.CCR-12-1063
84. Bohrer LR, Schwertfeger KL. Macrophages promote fibroblast growth factor receptor-driven tumor cell migration and invasion in a CXCR2-dependent manner. Mol Cancer Res (2012) 10:1294-305. doi:10.1158/1541-7786.MCR-12-0275
85. Fuchs K, Hippe A, Schmaus A, Homey B, Sleeman JP, Orian-Rousseau V. Opposing effects of high-and low-molecular weight hyaluronan on CXCL12-induced CXCR4 signaling depend on CD44. Cell Death Dis (2013) 4:e819. doi:10.1038/cddis.2013.364
86. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood (2006) 107:1761-7. doi:10.1182/blood-2005-08-3182
87. 2) and the nuclear factor-kappaB (NF-kappaB) pathway. J Biol Chem (2010) 285:24639-45. doi:10.1074/jbc.M110.134536
88. Bohrer LR, Chuntova P, Bade LK, Beadnell TC, Leon RP, Brady NJ, et al. Activation of the FGFR-STAT3 pathway in breast cancer cells induces a hyaluronan-rich microenvironment that licenses tumor formation. Cancer Res (2014) 74:374-86. doi:10.1158/0008-5472.CAN-13-2469
89. Puissant E, Gilis F, Dogne S, Flamion B, Jadot M, Boonen M. Subcellular trafficking and activity of Hyal-1 and its processed forms in murine macrophages. Traffic (2014) 15:500-15. doi:10.1111/tra.12162
90. Riabov V, Gudima A, Wang N, Mickley A, Orekhov A, Kzhyshkowska J. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol (2014) 5:75. doi:10.3389/fphys.2014.00075
91. Krejcova D, Pekarova M, Safrankova B, Kubala L. The effect of different molecular weight hyaluronan on macrophage physiology. Neuro Endocrinol Lett (2009) 30(Suppl 1):106-11.
92. Foley JP, Lam D, Jiang H, Liao J, Cheong N, Mcdevitt TM, et al. Toll-like receptor 2 (TLR2), transforming growth factor-beta, hyaluronan (HA), and receptor for HA-mediated motility (RHAMM) are required for surfactant protein A-stimulated macrophage chemotaxis. J Biol Chem (2012) 287:37406-19. doi:10.1074/jbc.M112.360982
93. Hart SP, Rossi AG, Haslett C, Dransfield I. Characterization of the effects of cross-linking of macrophage CD44 associated with increased phagocytosis of apoptotic PMN. PLoS One (2012) 7:e33142. doi:10.1371/journal.pone.0033142
94. Zaman A, Cui Z, Foley JP, Zhao H, Grimm PC, Delisser HM, et al. Expression and role of the hyaluronan receptor RHAMM in inflammation after bleomycin injury. Am J Respir Cell Mol Biol (2005) 33:447-54. doi:10.1165/rcmb.2004-0333OC
95. Jiang D, Liang J, Noble PW. Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol (2007) 23:435-61. doi:10.1146/annurev.cellbio.23.090506.123337
96. Campo GM, Avenoso A, Campo S, D'Ascola A, Nastasi G, Calatroni A. Small hyaluronan oligosaccharides induce inflammation by engaging both toll-like-4 and CD44 receptors in human chondrocytes. Biochem Pharmacol (2010) 80:480-90. doi:10.1016/j.bcp.2010.04.024
97. Yang H, Zhou H, Feng P, Zhou X, Wen H, Xie X, et al. Reduced expression of toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J Exp Clin Cancer Res (2010) 29:92. doi:10.1186/1756-9966-29-92
98. Harmey JH, Bucana CD, Lu W, Byrne AM, Mcdonnell S, Lynch C, et al. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer (2002) 101:415-22. doi:10.1002/ijc.10632
99. Ahmed A, Redmond HP, Wang JH. Links between toll-like receptor 4 and breast cancer. Oncoimmunology (2013) 2:e22945. doi:10.4161/onci.22945
100. Ghochikyan A, Pichugin A, Bagaev A, Davtyan A, Hovakimyan A, Tukhvatulin A, et al. Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax(R), as a therapeutic strategy for metastatic breast cancer. J Transl Med (2014) 12:322. doi:10.1186/s12967-014-0322-y
101. Chow A, Zhou W, Liu L, Fong MY, Champer J, Van Haute D, et al. Macrophage immunomodulation by breast cancer-derived exosomes requires toll-like receptor 2-mediated activation of NF-kappaB. Sci Rep (2014) 4:5750. doi:10.1038/srep05750
102. Milner CM, Day AJ. TSG-6: a multifunctional protein associated with inflammation. J Cell Sci (2003) 116:1863-73. doi:10.1242/jcs.00407
103. Lesley J, Gal I, Mahoney DJ, Cordell MR, Rugg MS, Hyman R, et al. TSG-6 modulates the interaction between hyaluronan and cell surface CD44. J Biol Chem (2004) 279:25745-54. doi:10.1074/jbc.M313319200
104. Baranova NS, Nileback E, Haller FM, Briggs DC, Svedhem S, Day AJ, et al. The inflammation-associated protein TSG-6 cross-links hyaluronan via hyaluronan-induced TSG-6 oligomers. J Biol Chem (2011) 286:25675-86. doi:10.1074/jbc.M111.247395
105. Jung S, Lee S, Lee J, Li C, Ohk JY, Jeong HK, et al. Protein expression pattern in response to ionizing radiation in MCF-7 human breast cancer cells. Oncol Lett (2012) 3:147-54. doi:10.3892/ol.2011.444
106. DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov (2011) 1:54-67. doi:10.1158/2159-8274.CD-10-0028
107. Mao Y, Qu Q, Zhang Y, Liu J, Chen X, Shen K. The value of tumor infiltrating lymphocytes (TILs) for predicting response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis. PLoS One (2014) 9:e115103. doi:10.1371/journal.pone.0115103
108. Evanko SP, Potter-Perigo S, Bollyky PL, Nepom GT, Wight TN. Hyaluronan and versican in the control of human T-lymphocyte adhesion and migration. Matrix Biol (2012) 31:90-100. doi:10.1016/j.matbio.2011.10.004
109. Ruffell B, Johnson P. Hyaluronan induces cell death in activated T cells through CD44. J Immunol (2008) 181:7044-54. doi:10.4049/jimmunol.181.10.7044
110. Bollyky PL, Lord JD, Masewicz SA, Evanko SP, Buckner JH, Wight TN, et al. Cutting edge: high molecular weight hyaluronan promotes the suppressive effects of CD4+CD25+ regulatory T cells. J Immunol (2007) 179:744-7. doi:10.4049/jimmunol.179.2.744
111. Nagy N, Kuipers HF, Frymoyer AR, Ishak HD, Bollyky JB, Wight TN, et al. 4-Methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer. Front Immunol (2015) 6:123. doi:10.3389/fimmu.2015.00123
112. Kultti A, Pasonen-Seppanen S, Jauhiainen M, Rilla KJ, Karna R, Pyoria E, et al. 4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3. Exp Cell Res (2009) 315:1914-23. doi:10.1016/j.yexcr.2009.03.002
113. Saito T, Tamura D, Nakamura T, Makita Y, Ariyama H, Komiyama K, et al. 4-methylumbelliferone leads to growth arrest and apoptosis in canine mammary tumor cells. Oncol Rep (2013) 29:335-42. doi:10.3892/or.2012.2100
114. Lokeshwar VB, Lopez LE, Munoz D, Chi A, Shirodkar SP, Lokeshwar SD, et al. Antitumor activity of hyaluronic acid synthesis inhibitor 4-methylumbelliferone in prostate cancer cells. Cancer Res (2010) 70:2613-23. doi:10.1158/0008-5472.CAN-09-3185
115. Piccioni F, Malvicini M, Garcia MG, Rodriguez A, Atorrasagasti C, Kippes N, et al. Antitumor effects of hyaluronic acid inhibitor 4-methylumbelliferone in an orthotopic hepatocellular carcinoma model in mice. Glycobiology (2012) 22:400-10. doi:10.1093/glycob/cwr158
116. 2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem-like cells with macrophages and stromal cells. Cancer Res (2012) 72:537-47. doi:10.1158/0008-5472.CAN-11-1678
117. Urakawa H, Nishida Y, Wasa J, Arai E, Zhuo L, Kimata K, et al. Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo. Int J Cancer (2012) 130:454-66. doi:10.1002/ijc.26014
118. Whatcott CJ, Han H, Posner RG, Hostetter G, Von Hoff DD. Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov (2011) 1:291-6. doi:10.1158/2159-8290.CD-11-0136
119. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell (2012) 21:418-29. doi:10.1016/j.ccr.2012.01.007
120. Jacobetz MA, Chan DS, Neesse A, Bapiro TE, Cook N, Frese KK, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut (2013) 62:112-20. doi:10.1136/gutjnl-2012-302529
121. Lee JH, Moore LD, Kumar S, Pritchard DG, Ponnazhagan S, Deivanayagam C. Bacteriophage hyaluronidase effectively inhibits growth, migration and invasion by disrupting hyaluronan-mediated Erk1/2 activation and RhoA expression in human breast carcinoma cells. Cancer Lett (2010) 298:238-49. doi:10.1016/j.canlet.2010.07.011
122. Shpilberg O, Jackisch C. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. Br J Cancer (2013) 109:1556-61. doi:10.1038/bjc.2013.371
123. Campbell JJ, Davidenko N, Caffarel MM, Cameron RE, Watson CJ. A multifunctional 3D co-culture system for studies of mammary tissue morphogenesis and stem cell biology. PLoS One (2011) 6:e25661. doi:10.1371/journal.pone.0025661
124. Hiscox S, Baruha B, Smith C, Bellerby R, Goddard L, Jordan N, et al. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. BMC Cancer (2012) 12:458. doi:10.1186/1471-2407-12-458
125. Montgomery N, Hill A, Mcfarlane S, Neisen J, O'Grady A, Conlon S, et al. CD44 enhances invasion of basal-like breast cancer cells by upregulating serine protease and collagen-degrading enzymatic expression and activity. Breast Cancer Res (2012) 14:R84. doi:10.1186/bcr3199
126. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer (2010) 46:1271-7. doi:10.1016/j.ejca.2010.02.024
127. Mummert ME, Mohamadzadeh M, Mummert DI, Mizumoto N, Takashima A. Development of a peptide inhibitor of hyaluronan-mediated leukocyte trafficking. J Exp Med (2000) 192:769-79. doi:10.1084/jem.192.6.769
128. Khurana SS, Riehl TE, Moore BD, Fassan M, Rugge M, Romero-Gallo J, et al. The hyaluronic acid receptor CD44 coordinates normal and metaplastic gastric epithelial progenitor cell proliferation. J Biol Chem (2013) 288:16085-97. doi:10.1074/jbc.M112.445551
129. Campo GM, Avenoso A, D'Ascola A, Nastasi G, Micali A, Puzzolo D, et al. Combined treatment with hyaluronan inhibitor Pep-1 and a selective adenosine A2 receptor agonist reduces inflammation in experimental arthritis. Innate Immun (2013) 19:462-78. doi:10.1177/1753425912470391
130. Campo GM, Micali A, Avenoso A, D'Ascola A, Scuruchi M, Pisani A, et al. Inhibition of small HA fragment activity and stimulation of A adenosine receptor pathway limit apoptosis and reduce cartilage damage in experimental arthritis. Histochem Cell Biol (2015) 143(5):531-43. doi:10.1007/s00418-014-1298-7